Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by RA Capital Management L.P.

RA Capital Management L.P. lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,689,190 shares of the company's stock after buying an additional 485,436 shares during the period. Vaxcyte makes up about 11.4% of RA Capital Management L.P.'s holdings, making the stock its 2nd biggest holding. RA Capital Management L.P. owned 6.97% of Vaxcyte worth $992,914,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Riverview Trust Co acquired a new position in shares of Vaxcyte during the 3rd quarter valued at $27,000. Fifth Third Bancorp acquired a new position in shares of Vaxcyte during the second quarter worth about $35,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares in the last quarter. J.Safra Asset Management Corp grew its stake in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after buying an additional 526 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at about $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.49, for a total value of $739,920.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at $19,024,730.55. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total value of $1,386,750.00. Following the completion of the sale, the chief executive officer now owns 450,301 shares in the company, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,464 shares of company stock worth $11,924,596. 3.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Leerink Partners boosted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. Jefferies Financial Group lifted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Finally, Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average target price of $147.50.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX traded down $2.89 during trading on Thursday, reaching $90.15. 674,798 shares of the company's stock traded hands, compared to its average volume of 904,941. The stock has a market capitalization of $11.24 billion, a P/E ratio of -20.23 and a beta of 0.94. Vaxcyte, Inc. has a 12 month low of $53.41 and a 12 month high of $121.06. The company has a 50 day moving average of $104.28 and a 200-day moving average of $90.73.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) EPS. Equities research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.